Comparative Study of First- And Second-Generation Antipsychotics in Schizophrenia

Abstract

Schizophrenia is a long-term mental illness that needs long-term antipsychotic medication to deal with its many symptoms. The goal of this study was to assess the effectiveness and side effects of first-generation (typical) and second-generation (atypical) antipsychotics in people with schizophrenia. There were 100 patients in total, and they were split into two equal groups. One group got first-generation antipsychotic medication, and the other group got second-generation antipsychotic medication. The Positive and Negative Syndrome Scale (PANSS), the Simpson-Angus Scale (SAS), and the Clinical Global Impression (CGI) scale were all used to rate the intensity of symptoms, extrapyramidal side effects, and overall clinical improvement. The results showed that patients who were given second-generation antipsychotics had much lower PANSS and SAS scores and showed more clinical improvement on the CGI scale. The results were statistically significant (p < 0.05) and back up the idea that SGAs work better and are easier to handle than FGAs. This study shows how important it is to put SGAs first when treating schizophrenia with drugs in order to have better results and improve the quality of life for patients.